Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
537 Leser
Artikel bewerten:
(2)

Royal DSM: DSM receives positive EFSA opinion for methane-reducing feed additive Bovaer

Finanznachrichten News

HEERLEN, Netherlands, Nov. 19, 2021 /PRNewswire/ -- Royal DSM, a global purpose-led science-based company, today announces that it has received a positive European Food Safety Agency (EFSA) opinion for the use of its novel methane-reducing feed additive for ruminants, Bovaer, in the European Union. The EFSA opinion confirms that the feed additive reduces enteric methane emissions from dairy cows and is safe for the animal and the consumer. This opinion progresses the application to the final stage of approval from the European Commission Standing Committee on Plants, Animals, Food and Feed.

DSM Logo. (PRNewsFoto/DSM)

Bovaer is the result of a decade of scientific research, including more than 50 peer-reviewed studies published in independent scientific journals and 45 on-farm trials in 13 countries across 4 continents. Since receiving full regulatory approvals in Brazil and Chile for Bovaer in early September 2021, DSM has signed a development agreement with JBS S.A., one of the world's largest food producers. European Commission approval would allow DSM to start market development in Europe in the first half of 2022. DSM has already begun engineering for a new large scale production facility in Dalry, Scotland.

During the recent UN Climate Change Conference, COP26, governments of more than 100 countries pledged to cut methane emissions by 30% by 2030. Reducing methane, which is much more potent than carbon dioxide, was emphasized as a crucial way to keep within the Paris Agreement target of no more than 1.5 degrees Celsius of global warming.

Ivo Lansbergen, DSM's President, Animal Nutrition and Health, commented: "It is very timely, after the IPCC's climate change report and the recent Global Methane Pledge during COP26, that a positive opinion has been given for a feed additive that we know can have such a beneficial environmental impact. We see the livestock sector recognizes this opportunity for change and is eager to act. We are hopeful that the European Commission will approve the application with speed so that we can offer a scientifically proven effective answer to the challenge of farming's methane emissions."

DSM recently launched a series of new quantifiable commitments aimed to address urgent societal and environmental challenges linked to how the world produces and consumes food. DSM's Food System Commitments include a double-digit on-farm reduction of livestock emissions by 2030. The market introduction of Bovaer is a major step toward delivering on this commitment as well as the strategic initiative of DSM's Animal Nutrition & Health business, We Make it Possible, with its mission to lead a robust and achievable transformation worldwide in sustainable animal protein production.

About Bovaer
Bovaer is a feed additive for cows researched and developed over 10 years by DSM. Just a quarter teaspoon of Bovaer per cow per day consistently reduces enteric methane emission by approximately 30% for dairy cows and even higher percentages (up till 90%) for beef cows. The feed additive Bovaer therefore contributes to a significant and immediate reduction of the environmental footprint of meat, milk and dairy products. Bovaer is the most extensively studied and scientifically proven solution to the challenge of burped methane to date. Upon feeding, it takes effect immediately.

DSM
Royal DSM is a global, purpose-led company in Health, Nutrition & Bioscience, applying science to improve the health of people, animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders - customers, employees, shareholders, and society at large. DSM and its associated companies employ approximately 23,000 people around the world and deliver annual net sales of about €10 billion. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

Or find us on:

Facebook: http://www.facebook.com/DSMcompany
Twitter: http://www.twitter.com/DSM
LinkedIn: http://www.linkedin.com/company/3108
YouTube: http://www.youtube.com/user/dsmcompany

For more information:

DSM Media relations

Gareth Mead

tel. +31 (0) 45 5782420

email media.contacts@dsm.com


DSM Investor Relations

Dave Huizing

tel. +31 (0) 45 5782864

email investor.relations@dsm.com

Forward-looking statements
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

Logo - https://mma.prnewswire.com/media/329419/dsm_logo.jpg

© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.